Isomorphic Labs raises $5B Series C to advance AI-designed drug candidates toward clinical trials
Isomorphic Labs, the AI drug-discovery company spun out of Google's DeepMind in 2021, has raised a $5 billion Series C. Greenoaks and Sequoia Capital co-led the round, and new investor Andreessen Horowitz took part. Existing backers including GV, Capital G, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund also invested. The round follows a $2.1 billion Series B in May. The funds will go to the drug-design engine, which builds on AlphaFold, and to expansion into more types of medicine. The company did not disclose its valuation, though Bloomberg reported it was seeking about $50 billion. This is funding news with no cybersecurity threat, vulnerability or incident. It was drawn from the article alone, because no web research was done.
Linha do tempo
-
Isomorphic Labs raises $5B Series C to advance AI-designed drug candidates toward clinical trials
ler a análise desta fonte ocultar
Isomorphic Labs, the AI drug-discovery company spun out of Google's DeepMind in 2021, has raised a $5 billion Series C. Greenoaks and Sequoia Capital co-led the round, and new investor Andreessen Horowitz took part. Existing backers including GV, Capital G, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund also invested. The round follows a $2.1 billion Series B in May. The funds will go to the drug-design engine, which builds on AlphaFold, and to expansion into more types of medicine. The company did not disclose its valuation, though Bloomberg reported it was seeking about $50 billion. This is funding news with no cybersecurity threat, vulnerability or incident. It was drawn from the article alone, because no web research was done.